Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma

被引：45

作者：

Janik, JE

Morris, JC

Pittaluga, S

McDonald, K

Raffeld, M

Jaffe, ES

Grant, N

Gutierrez, M

Waldmann, TA

Wilson, WH

机构：

[1] NCI, Ctr Canc Res, Metab Branch, NIH, Bethesda, MD 20892 USA

[2] NCI, Ctr Canc Res, Hematopathol Sect, Lab Pathol,NIH, Bethesda, MD 20892 USA

[3] NCI, Ctr Canc Res, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA

来源：

BLOOD | 2004年 / 104卷 / 10期

关键词：

D O I：

10.1182/blood-2003-11-3922

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Levels of serum soluble interleukin 2 receptor (sIL-2R) provide a reliable marker of disease activity in patients with hairy cell leukemia and adult T-cell leukemia/lymphoma. The malignant cells in patients with anaplastic large cell lymphoma (ALCL) express CD30 and are usually positive for expression of CD25. We measured serum sIL-2R and soluble CD30 (sCD30) levels in patients with ALCL treated with EPOCH (etoposide, prednisone, Oncovin, Cytoxan, hydroxydaunorubicin) infusional chemotherapy. Serum sCD30 levels were elevated and decreased in response to therapy as previously reported. Serum sIL-2R levels were elevated in 7 of 9 patients with ALCL and decreased in response to treatment. Baseline serum sIL-2R levels varied but correlated well with serum sCD30 levels (r = 0.97). Patients positive for the anaplastic lymphoma kinase (ALK) gene showed elevated sIL-2R levels, whereas those negative for ALK had normal serum sIL-2R levels and their tumors lacked CD25 expression. Serum sIL-2R levels were elevated in both patients with recurrent disease. (C) 2004 by The American Society of Hematology.

引用

页码：3355 / 3357

页数：3

共 29 条

[1]

Arun B, 2000, CANCER J SCI AM, V6, P21

[2] Primary and secondary cutaneous CD30+ lymphoproliferative disorders:: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment [J].

Bekkenk, MW ;

Geelen, FAMJ ;

Vader, PCV ;

Heule, F ;

Geerts, ML ;

van Vloten, WA ;

Meijer, CJLM ;

Willemze, R .

BLOOD, 2000, 95 (12) :3653-3661

[3]

CARBONE A, 1990, CANCER, V66, P2547, DOI 10.1002/1097-0142(19901215)66:12<2547::AID-CNCR2820661217>3.0.CO

[4]

2-6

[5]

Chan WC, 1997, BLOOD, V89, P3909

[6]

Falini B, 1999, BLOOD, V93, P2697

[7] Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma [J].

Gascoyne, RD ;

Aoun, P ;

Wu, D ;

Chhanabhai, M ;

Skinnider, BF ;

Greiner, TC ;

Morris, SW ;

Connors, JM ;

Vose, JM ;

Viswanatha, DS ;

Coldman, A ;

Weisenburger, DD .

BLOOD, 1999, 93 (11) :3913-3921

[8]

GUTIERREZ ME, 2000, P AN M AM SOC CLIN, V19, P26

[9]

HARRIS NL, 1994, BLOOD, V84, P1361

[10] Anaplastic large cell lymphoma: The shifting sands of diagnostic hematopathology [J].

Jaffe, ES .

MODERN PATHOLOGY, 2001, 14 (03) :219-228

← 1 2 3 →